BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies

Date 03 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Epigenetics and chaperones
Topics Anticancer agents
Clinical research
Haematologic Malignancies
Basic Scientific Principles
Therapy
Biological therapy
Presenter Patrice Herait